Embla Genomics ApS: Financial statements 2023
CVR: 41685603
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Embla Genomics ApS (CVR 41685603) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -9,205 and a net result of DKK -10,591 compared with DKK -8,431 the year before. Equity in the 2023 report amounted to DKK 49,881. The solvency ratio was 100%.
- Gross Profit
- DKK -9,205
- Profit/Loss
- DKK -10,591
- Equity
- DKK 49,881
- Total Assets
- DKK 49,881
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Embla Genomics ApS has published its annual report for 2022. Gross profit came to DKK -10,007, and the net result was DKK -8,431.
About Embla Genomics ApS
Embla Genomics ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company has been dissolved on 19 October 2026. The company was registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company has 2 employees (2021). In 2025, the company reported a gross profit of DKK 14,722 and a net result of DKK 7,398 compared with DKK -7,604 the year before. Equity in the 2025 report amounted to DKK 49,675.